Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology returning to growth despite losing exclusivity on Stelara. Wolk explains why MedTech growth of about 2.5% needs to improve, how a new heart pump study and Middle East budgets factor in, and why prescriptions for J&J's new oral psoriasis pill are reaching beyond dermatologists. He also says Tremfya could become a more than $10 billion product, explains why J&J is leaning toward a spinoff of its orthopedics business rather than a sale, and discusses drug pricing pressure. Watch The 8:30 live weekdays 8:30-9:30am ET. 00:00 J&J raises its forecast again 00:17 Oncology, neuroscience and immunology 01:34 How J&J plans to fix MedTech 01:51 The heart pump study 02:20 Middle East budgets and MedTech demand 03:01 The new oral psoriasis pill 04:20 Why pills could expand the market 04:53 How long can Tremfya keep growing? 05:54 Why J&J is leaning toward an orthopedics spinoff 07:16 Drug pricing and the FDA #JohnsonAndJohnson #Earnings #Pharma #The830 #YahooFinance == AlphaSpace by Yahoo Finance: A Professional-Grade Investment Platform Built for Everyday Investors. 👉 https://finance.yahoo.com/about/promos/gold/alphaspace?ncid=100003571